Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240893 | 0.74 | ALDH1A1 (0.38) | KDM4EMAPTLMNACYP3A4CYP2D6 | |
| SCHEMBL5894605 | 0.74 | TDP1 (0.31) | KDM4EMAPTGMNNLMNATP53 | |
| SCHEMBL247478 | 0.72 | ALDH1A1 (0.41) | KDM4EMAPTLMNATP53HSP90AA1 | |
| SCHEMBL29364156 | 0.72 | ALDH1A1 (0.41) | KDM4EMAPTLMNATP53HSP90AA1 | |
| Bromide SCHEMBL7758538 | 0.72 | ALDH1A1 (0.37) | KDM4ELMNATSHRHTT | |
| SCHEMBL4779709 | 0.71 | NPC1 (0.44) | KDM4EMAPTLMNATP53HSP90AA1 | |
| Quinoxaline SCHEMBL5268892 | 0.71 | ALDH1A1 (0.35) | KDM4EMAPTTSHR | |
| SCHEMBL3874066 | 0.68 | — | — | |
| SCHEMBL14250227 | 0.68 | MAPK14 (0.41) | KDM4EMAPTLMNAHSP90AA1CCR1 | |
| SCHEMBL8389410 | 0.68 | MITF (0.34) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465465-B1 | PHOSPHODIESTERASE INHIBITORS | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-10-15 | — | — | US | claimed |
| US-20020147199-A1 | PROCESS FOR THE TREATMENT OF ERECTILE DYSFUNCTION AND PRODUCT THEREFOR | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-10-10 | — | — | US | claimed |
| EP-0736532-B1 | Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation | ASTA MEDICA AG (DE) | 2002-05-15 | — | — | EP | claimed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | claimed |
| EP-0736532-A1 | Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation | ASTA Medica Aktiengesellschaft (DE) | 1996-10-09 | — | — | EP | claimed |
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-10-16 | — | — | US | disclosed |
| EP-3074395-B1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECH LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9708317-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-B]pyrazin-3-one derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20160297814-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | OXY SCIENTIFIC LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| WO-2001068097-A1 | USE OF PYRIDO[3,2-E]-PYRAZINONES AS INHIBITORS OF PHOSPHODIESTERASE 5 FOR TREATING ERECTILE DYSFUNCTION | ELBION AG (DE) | 2001-09-20 | — | — | WO | disclosed |
| CN-1058968-C | Novel pyrido [3,2-e] pyrazinones with anti-asthmatic action and processes for their manufacture | ASTA MEDICA AG (DE) | 2000-11-29 | — | — | CN | disclosed |
| WO-2000043392-A2 | USE OF IMIDAZO[1,5-A]-PYRIDO[3,2-E]-PYRAZINONES AS MEDICAMENTS | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2000-07-27 | — | — | WO | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| CN-1140173-A | Novel pyrido [3,2-e] pyrazinones with anti-asthmatic action and processes for their manufacture | ASTA MEDICA AG (DE) | 1997-01-15 | — | — | CN | disclosed |
| EP-0736532-A1 | Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation | ASTA Medica Aktiengesellschaft (DE) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736532-A1 | Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation | ASTA Medica Aktiengesellschaft (DE) | 1996-10-09 | — | — | EP | disclosed |
| EP-0736532-A1 | Pyrido(3,2-e)pyrazinones with antiasthmatic activity and process for their preparation | ASTA Medica Aktiengesellschaft (DE) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100053-B2 | Process for the preparation of 8-(4-aminophenoxy)-4H-pyrido[2,3-b]pyrazin-3-one derivatives | PAM, PDXK, GRHPR | NUDT1 186/4885KDM4E 377/4885MAPT 2753/4885 |
| US-20020147199-A1 | PROCESS FOR THE TREATMENT OF ERECTILE DYSFUNCTION AND PRODUCT THEREFOR | PDE5A, PDE3A, PDE3B | NUDT1 726/4885KDM4E 1002/4885MAPT 3543/4885 |
| US-20170298065-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | TDO2, HPD, PDXK | NUDT1 1324/4885KDM4E 58/4885MAPT 3185/4885 |
| US-20160297814-A1 | PROCESS FOR THE PREPARATION OF 8-(4-AMINOPHENOXY)-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE DERIVATIVES | PAM, PDXK, GRHPR | NUDT1 186/4885KDM4E 377/4885MAPT 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.